NERATINIB | NERATINIB | ATC L01XE45
ANTINEOPLASTIC TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER EGFR KINASE INHIBITOR HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) AND HER4 INHIBITOR | ORAL | Tmax 5 HOUR VD 6433 LITER PPB 99 PERCENT Cl 281 LITER / HOUR HT 14.6 HOUR SOLUBILITY SPARINGLY SOLUBLE AT PH 1.2 (32.90 MG/ML) AND INSOLUBLE AT APPROXIMATE PH 5.0 AND ABOVE (0.08 MG/ML OR LESS) | EGFR HER2 HER4 | ENZYME EGFR_HUMAN INHIBITOR P00533 ERBB2_HUMAN INHIBITOR P04626 ERBB4_HUMAN INHIBITOR Q15303 | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |